In the most recent trading session, Novavax (NVAX) closed at $12.06, indicating a +1.34% shift from the previous trading day.
During May and June, Novavax (NASDAQ: NVAX ) shares appeared to be making a major comeback. At the time, news of a partnership deal with pharma firm Sanofi (NASDAQ: SNY ), as well as another positive development, were driving Novavax stock “to the moon.
Nvidia (NASDAQ: NVDA ) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami.
Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works.
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ: NVAX ) the green light to target a specific Covid-19 variant.
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
It was not long ago that Novavax (NASDAQ: NVAX ) was among the stocks with high short interest. The stock had been trending lower for an extended period.
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.